After migraine accord with Eli Lilly, Organon CEO scouts more deals to bolster growth
Reflecting on the European launch of Emgality—which Eli Lilly considers one of its key growth products—Organon CEO Kevin Ali said his company sees the potential for the drug to reach $170 million in peak sales. (MicroStockHub/iStock/Getty Images Plus)